The Aesthetics Advisor

If there's anything the Ozempic craze has taught us, it's that people are hungry for weight loss solutions. But as the world leans into wellness, many are now looking beyond pharmaceuticals, turning their gaze to nature's arsenal for blood sugar balance and metabolic health. The 2023 report from the World Obesity Federation estimates that the economic impact of overweight and obesity will surpass $4.3 trillion annually by 2035. In the U.S., the CDC  reports the prevalence of obesity in adults was 41.9% measured from 2017 to March 2020. This represented an increase from 30.5% from 1999 to 2000. The estimated annual medical costs were roughly $173 billion in 2019 dollars. The weight loss and weight management diet market size was valued at 192.2 billion in 2019, and is projected reach $295.3 billion by 2027, registering a CAGR of 7.0% from 2021 to 2027. ( source ) Prescriptions for semaglutide have doubled since mid-2021, rising to mor...

Introduction The landscape of obesity treatment has evolved dramatically with the introduction of advanced medical therapeutics like retatrutide (RETA, LY3437943), tirzepatide, and semaglutide. These drugs, originally developed to manage type 2 diabetes, have shown remarkable efficacy in promoting weight loss, making them game-changers for obesity management. However, each drug has unique mechanisms, benefits, and potential applications, including emerging roles in cancer prevention. This article compares retatrutide, tirzepatide, and semaglutide, highlighting their differences in mechanism of action, weight loss efficacy, additional health benefits, and side effects to help patients and healthcare providers make informed decisions. Mechanism of Action Semaglutide : Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). It mimics the action of GLP-1, a hormone that enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. Mar...